Duopharma Biotech Berhad (KLSE:DPHARMA)

Malaysia · Delayed Price · Currency is MYR

1.280

-0.020 (-1.54%)

At close: Aug 28, 2026

-6.57% (1Y)

Market Cap	1.23B -6.6%
Revenue (ttm)	929.41M +4.8%
Net Income	102.21M +33.6%
EPS	0.11 +33.4%
Shares Out	961.94M
PE Ratio	12.05
Forward PE	11.62
Dividend	0.05 (3.67%)
Ex-Dividend Date	Sep 3, 2026

Volume	283,500
Open	1.310
Previous Close	1.300
Day's Range	1.280 - 1.310
52-Week Range	1.180 - 1.570
Beta	0.35
Analysts	Strong Buy
Price Target	1.68 (+31.25%)
Earnings Date	Nov 6, 2026

About Duopharma Biotech Berhad

Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain... [Read more]

Industry Pharmaceutical Preparations

Founded 1978

Employees 1,957

Stock Exchange Bursa Malaysia

Ticker Symbol DPHARMA

Full Company Profile

Financial Performance

In 2025, Duopharma Biotech Berhad's revenue was 931.69 million, an increase of 14.50% compared to the previous year's 813.70 million. Earnings were 87.46 million, an increase of 39.62%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for DPHARMA stock is "Strong Buy." The 12-month stock price target is RM 1.68, which is an increase of 31.25% from the latest price.

Price Target

RM 1.68

(31.25% upside)

Analyst Consensus: Strong Buy

Stock Forecasts